Cardio Diagnostics (CDIO)
Develops genetic-epigenetic blood tests and clinical intelligence for coronary heart disease.
Something off on this page? Send us feedback.
Provides prescription blood tests for coronary-heart-disease risk assessment and detection, combining genetic and epigenetic biomarkers with predictive models. Revenue is reported entirely in product testing, while clinical adoption depends on reimbursement, guidelines and provider workflow integration.
Transforms genetic, DNA-methylation and clinical data into biomarker panels, laboratory assays and interpretive models for prescription blood tests. Epi+Gen CHD assesses coronary-heart-disease event risk, while PrecisionCHD detects and helps manage the disease; Actionable Clinical Intelligence links patient profiles to modifiable pathways.
Operates the clinical tests as laboratory-developed tests through a high-complexity CLIA-certified, state-licensed laboratory, assembling blood-collection kits internally and sourcing proprietary genetic and DNA-methylation components from outside manufacturers. Commercial activity is primarily U.S.-focused across providers, health systems, employers and payors, with a partner-led implementation in India.
Extends the portfolio with HeartRisk population-risk intelligence and CardioInnovate360 biopharma research support. Broad adoption depends on payor coverage, clinical-guideline inclusion, provider-workflow integration and continuing evidence; core patent rights are exclusively licensed from the University of Iowa Research Foundation.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $5.6M · Total debt $369.7K · Total assets $7.9M · Shareholders' equity $7.4M
- Revenue
- $5.4K
- Operating income
- −$1.5M
- Net income
- −$1.5M
No dividends on record.
| Institutions | 6.52% | 193.0K shares | |
|---|---|---|---|
| 17 holders · as of Jun 30, 2026 | |||
| Insiders | 2.09% | 61.8K shares | |
| 2 holders · as of Oct 9, 2024 | |||
| Other | 91.39% | 2.70M shares | |
| remainder | |||
2.96M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Meeshanthini DoganInsiderdirector, officer: Chief Executive Officer | 1.86% | 55,181 | filed Oct 8, 2024 |
Renaissance Technologies LLCInstitution | 1.66% | 49,200 | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 1.17% | 34,708 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.89% | 26,233 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 0.68% | 20,155 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Quest Diagnostics
Advanced blood panels contest preventive cardiovascular-risk testing.
- Labcorp
NMR lipid profiling contests blood-based cardiovascular-risk testing.
- Abbott
Cardiac biomarker assays contest CHD-risk and acute-detection testing.
- GE HealthCare
Cardiac CT contests coronary-disease diagnostic workflows.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cardio Diagnostics | $1.90 | −1.04% | $5.7M | — | — | 393.2 | −28.3% |
| Quest Diagnostics | $237.42 | +1.13% | $25.92B | 24.9 | 20.7 | 2.2 | +10.2% |
| Labcorp | $311.75 | +0.07% | $25.55B | 25.8 | 16.5 | 1.8 | +5.8% |
| Abbott | $104.04 | +0.30% | $179.49B | 33.4 | 18.0 | 3.9 | +13.0% |
| GE HealthCare | $65.79 | −0.72% | $29.93B | 19.2 | 12.7 | 1.5 | +5.8% |
| Median | 25.3 | 17.2 | 2.0 | +8.0% |